Medication approval journey
modafinil (Provigil)
Approved for Excessive sleepiness in narcolepsy (later OSA and shift work disorder)
Before changing anything
Low risk from stopping, but still worth planning
Stopping modafinil does not cause a dangerous withdrawal syndrome — the sleepiness it was treating comes back, which is worth planning for but not dangerous in itself. The fact most worth carrying is an interaction: modafinil can make hormonal contraception less effective, during use and for a month after stopping. It is also a controlled substance (Schedule IV).
How long the trials actually ran
The longest trial behind the modafinil approval ran 9 weeks.
The gap between how long the trials ran and how long people actually take these medications is the single most important thing on this page. It is not evidence that longer use is unsafe or ineffective. It is evidence that longer use was not what got tested.
How many Americans take modafinil
Survey-based federal estimates, published with a lag of about two years. They count prescriptions filled, not outcomes.
- 1,056,221
- prescriptions in the United States (2020)
- 233,071
- people filling them (2020)
Prescriptions are down 1% since 2015. Whatever you decide about modafinil, you are deciding alongside about 233,071 other people this year.
Source: ClinCalc DrugStats (Medical Expenditure Panel Survey (MEPS), Agency for Healthcare Research and Quality), CC BY-SA 4.0, release 2026.08.
What people report to the FDA about modafinil
Read this before the numbers.
Anyone can file an adverse event report — patients, doctors, manufacturers — and nobody verifies that the drug caused what was reported. There is no denominator: tens of millions of prescriptions generate reports at an unknowable rate, and reporting rises with news coverage, not necessarily with harm. Counts below are report volumes, not rates, and cannot be compared between drugs. The FDA itself says not to use this data to make medical decisions — we show it because you deserve to see what is in the public record, with its limits stated plainly.
- 32,106
- reports mentioning modafinil, all time
- 18,649
- filed as serious (a report-level flag covering every drug and outcome in the report)
Most-reported reactions
- Fatigue2,949
- Nausea2,248
- Drug ineffective2,140
- Headache1,870
- Fall1,794
- Depression1,619
- Anxiety1,503
- Somnolence1,419
- Dizziness1,404
- Pain1,291
“Drug ineffective” ranking this high is worth noticing: a report of not being helped counts as an adverse event too, and people file them in large numbers.
Source: FDA Adverse Event Reporting System (FAERS), via openFDA, data through 2026-07-30.
Known interactions, from the label
The FDA label’s interactions section, verbatim. A pharmacist checking your actual medication list beats any published list — including this one.
Read the label’s interactions section
7 DRUG INTERACTIONS Effects of Modafinil Tablets on CYP3A4/5 Substrates The clearance of drugs that are substrates for CYP3A4/5 (e.g., steroidal contraceptives, cyclosporine, midazolam, and triazolam) may be increased by modafinil tablets via induction of metabolic enzymes, which results in lower systemic exposure. Dosage adjustment of these drugs should be considered when these drugs are used concomitantly with modafinil tablets [see Clinical Pharmacology ( 12.3 )] . The effectiveness of steroidal contraceptives may be reduced when used with modafinil tablets and for one month after discontinuation of therapy. Alternative or concomitant methods of contraception are recommended for patients taking steroidal contraceptives (e.g., ethinyl estradiol) when treated concomitantly with modafinil tablets and for one month after discontinuation of modafinil tablets treatment. Blood levels of cyclosporine may be reduced when used with modafinil tablets. Monitoring of circulating cyclosporine concentrations and appropriate dosage adjustment for cyclosporine should be considered when used concomitantly with modafinil tablets. Effects of Modafinil Tablets on CYP2C19 Substrates Elimination of drugs that are substrates for CYP2C19 (e.g., phenytoin, diazepam, propranolol, omeprazole, and clomipramine) may be prolonged by modafinil tablets via inhibition of metabolic enzymes, with resultant higher systemic exposure. In individuals deficient in the CYP2D6 enzyme, the levels of CYP2D6 substrates which have ancillary routes of elimination through CYP2C19, such as tricyclic antidepressants and selective serotonin reuptake inhibitors, may be increased by co-administration of modafinil tablets. Dose adjustments of these drugs and other drugs that are substrates for CYP2C19 may be necessary when used concomitantly with modafinil tablets [see Clinical Pharmacology ( 12.3 )] . Warfarin More frequent monitoring of prothrombin times/INR should be considered whenever modafinil tablets are coadministered with warfarin [see Clinical Pharmacology ( 12.3 )] . Monoamine Oxidase (MAO) Inhibitors Caution should be used when concomitantly administering MAO inhibitors and modafinil tablets. Steroidal contraceptives (e.g., ethinyl estradiol): Use alternative or concomitant methods of contraception while taking modafinil tablets and for one month after discontinuation of modafinil tablets treatment. ( 7 ) Cyclosporine: Blood concentrations of cyclosporine may be reduced. ( 7 ) CYP2C19 substrates, such as omeprazole, phenytoin, and diazepam: Exposure of these medications may be increased. ( 7 )
FDA label for modafinil, effective July 21, 2026 — DailyMed.
Who pays for modafinil
Two claims datasets and one survey, covering different populations with different instruments — they cannot be reconciled by arithmetic, and where their sum crowds the all-payer estimate, that is a finding about the estimates rather than a percentage.
- Medicare Part D
- 75,412 beneficiaries filled 369,049 claims in 2024 — 52,608 aged 65 and over, and 22,804 under 65. The under-65 group is not a picture of ordinary working-age adults: Medicare before 65 means the disabled and dual-eligible population — among the sickest, highest-need people in the program — and reading their utilization as typical adult use would be a category error.
- Medicaid
- At least 129,399 prescriptions in 2024 — a floor, because 58 of 295 national data rows are suppressed for privacy and contribute zero. Medicaid covers more children than any insurer in the country and publishes no age split — how much of this number is pediatric use is not knowable from public data.
- All payers (survey estimate)
- The MEPS-based estimate above puts the whole country at 1,056,221 prescriptions and 233,071 people in 2020. Subtracting the public programs from it would produce a number for everyone else — and we do not print that number, because subtracting a survey from claims counts manufactures precision that does not exist.
- The population nobody counts
- The commercially insured working-age adult — statistically, the likeliest person to be reading this page — is the one population with no public per-drug count anywhere. Private claims data exists and is sold, but nothing a patient can check is published. For children the record is thinner still: no public source counts pediatric use of modafinil specifically; the closest the public record comes is condition-level treatment rates for children, which we have traced for one condition in how childhood ADHD got counted.
Sources: Medicare Part D Prescribers — by Geography and Drug, data.cms.gov, National rows, data year 2024 (published with ~17-month lag). Medicaid State Drug Utilization Data 2024, data.medicaid.gov, national aggregate rows. Retrieved 2026-09-01.
The approval, step by step
Step 1
What the approval was actually based on
Which studies did the FDA rely on, how long did they run, and who was in them?
The effectiveness of PROVIGIL in improving wakefulness in adult patients with excessive sleepiness associated with narcolepsy was established in two US 9-week, multi-center, placebo-controlled, parallel-group, double-blind studies of outpatients who met the criteria for narcolepsy. A total of 558 patients were randomized to receive PROVIGIL 200 or 400 mg/day, or placebo.
FDA-approved labelling, 14 CLINICAL STUDIES — read the label on DailyMed
Our reading
Two nine-week trials in 558 people with narcolepsy — a real package for a real indication. The gap between that sentence and how this drug circulates is the story: modafinil's reputation as a focus and productivity drug rests on zero of the evidence on this label, which never studied healthy people, students, or anyone's job performance. The label fact that deserves to be famous instead: modafinil induces the enzymes that clear hormonal contraceptives, reducing their effectiveness during use and for a month after stopping.
Step 2
The approval
When was it approved, under what application, and by whose review?
- Approved
- December 24, 1998
- Application
- NDA020717
- Review
- STANDARD
- Original sponsor
- Cephalon (application now held by Nuvo)
- Holds it now
- Nuvo Pharmaceuticals
- Label submissions since
- 30
Source: openFDA Drugs@FDA, original application ORIG-1
Step 3
What was added after it was on the market
Which warnings arrived only after millions of people were already taking it?
We have not recorded a post-approval change to the modafinil label. That is the state of our record, not a finding that nothing was ever added.
Step 4
What independent research has found since
What has been learned by people who were not selling it?
We have not yet added independent post-approval research on modafinil to the evidence library. Absence here means we have not covered it, not that none exists.
Step 5
What still is not known
Which questions you might reasonably have has nobody answered yet?
- The approval evidence is about narcolepsy and sleep disorders. If the prescription is for anything else, what evidence is it resting on?
- Hormonal contraception becomes less reliable on this drug and for a month after. Has that conversation happened?
- Schedule IV is a dependence classification. What does the label say about misuse, and what does year-after-year use look like?
Deciding about modafinil?
- 12 questions to ask before starting a psychiatric medication — each with the study behind it
- Already on it? The 10-question annual review — including the honest case for staying
- How long every drug here was tested before approval — one chart, all medications
Open modafinil (Provigil) in Resolv
The app has the full approval journey, the resources behind it, and people working through the same questions.
